Autopsy report · NCT06302400
Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Cause of deathDrug or device supply
“Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range”
Life of this trial
- Ran for about 1 year before it stopped.
- 4 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- 166Holmium microspheres (QuiremSpheres®)
- Participants
- 4
- Sites
- 1
- Countries
- United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.